Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome (Q74066644)
scientific article published on 01 November 1997
Language:
(P31) (Q13442814)
(P304) 171-173
(P407) (Q1860)
(P433) 3-4
(P478) 45
(P577) Saturday, November 1, 1997
Saturday, November 1, 1997
(P921) (Q4833719)
(Q60341073)
(P953) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037658
https://europepmc.org/articles/PMC11037658
https://europepmc.org/articles/PMC11037658?pdf=render
https://doi.org/10.1007/s002620050425
http://link.springer.com/content/pdf/10.1007/s002620050425.pdf
http://link.springer.com/article/10.1007/s002620050425/fulltext.html
http://link.springer.com/content/pdf/10.1007/s002620050425
(P1433) (Q5031409)
(P1476) "Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome" (language: en)
(P2093) J. Honeychurch
A. Cruise
A. L. Tutt
M. J. Glennie
other details
description scientific article published on 01 November 1997

External Links